Valeant Suffers Biggest Drop on Record, What's Next?

Valeant Pharmaceuticals International Inc. shares plunged in their worst day ever, falling as much as 49 percent after the company cut its 2016 forecast, reported a weak fourth quarter and said it risked breaching some of its debt agreements if it can’t file its annual report in time. Livermore Partners Managing Director David Neuhauser weighs in on "Bloomberg Markets." (Source: Bloomberg)

Economist Hooper Sees Fed Holding to 2018 Expectations
48:39 - Peter Hooper, chief economist at Deutsche Bank AG, and Peter Schaffrik, global macro strategist at RBC Europe, preview this week's Federal Reserve interest rate decision and how the Fed's dot plot may change. They speak with Bloomberg's Alix Steel on "Bloomberg Daybreak: Americas." (Source: Bloomberg)
  • Jefferies Trading Revenue Tumbles Amid Industry Decline
  • Trump Says Iran Nuclear Deal Is 'Embarrassment' to U.S.
  • Perella CEO Bob Steel on Inclusive Growth, M&A